Neurocrine Biosciences (NBIX) Long-Term Investments (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Long-Term Investments for 17 consecutive years, with $1.3 billion the latest figure, recorded in Q1 2026.

• Long-Term Investments for Q1 2026 came in at $1.3 billion, up 63.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 63.25% YoY), and the FY2025 annual result was $1.1 billion, up 43.75% from the prior year.
• Long-Term Investments was $1.3 billion for Q1 2026 at Neurocrine Biosciences, up from $1.1 billion in the prior quarter.
• Over five years, Long-Term Investments peaked at $1.3 billion in Q1 2026 and troughed at $244.6 million in Q1 2023.
• Average Long-Term Investments over 5 years is $655.3 million, with a median of $643.9 million recorded in 2024.
• Year-over-year, Long-Term Investments tumbled 54.79% in 2023 and jumped 186.35% in 2024.
• Over 5 years, Long-Term Investments stood at $299.4 million in 2022, then soared by 129.63% to $687.5 million in 2023, then gained by 7.56% to $739.5 million in 2024, then soared by 43.75% to $1.1 billion in 2025, then climbed by 25.21% to $1.3 billion in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $1.3 billion in Q1 2026, $1.1 billion in Q4 2025, and $998.5 million in Q3 2025.